APG Asset Management N.V. boosted its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 1,614,489 shares of the biopharmaceutical company’s stock after acquiring an additional 44,300 shares during the period. APG Asset Management N.V. owned 0.10% of Bristol-Myers Squibb worth $102,908,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BMY. Douglas Lane & Associates LLC grew its holdings in shares of Bristol-Myers Squibb by 21.7% in the 3rd quarter. Douglas Lane & Associates LLC now owns 865,291 shares of the biopharmaceutical company’s stock valued at $55,154,000 after buying an additional 154,208 shares during the period. Farmers & Merchants Investments Inc. grew its holdings in shares of Bristol-Myers Squibb by 3.8% in the 3rd quarter. Farmers & Merchants Investments Inc. now owns 105,664 shares of the biopharmaceutical company’s stock valued at $6,735,000 after buying an additional 3,881 shares during the period. Guardian Investment Management grew its holdings in shares of Bristol-Myers Squibb by 2.6% in the 3rd quarter. Guardian Investment Management now owns 40,115 shares of the biopharmaceutical company’s stock valued at $2,556,000 after buying an additional 1,000 shares during the period. Honkamp Krueger Financial Services Inc. grew its holdings in shares of Bristol-Myers Squibb by 12.4% in the 3rd quarter. Honkamp Krueger Financial Services Inc. now owns 17,193 shares of the biopharmaceutical company’s stock valued at $1,096,000 after buying an additional 1,890 shares during the period. Finally, Kistler Tiffany Companies LLC grew its holdings in shares of Bristol-Myers Squibb by 15.0% in the 3rd quarter. Kistler Tiffany Companies LLC now owns 15,230 shares of the biopharmaceutical company’s stock valued at $971,000 after buying an additional 1,987 shares during the period. 69.66% of the stock is owned by hedge funds and other institutional investors.

Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $61.20 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Co has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a market cap of $100,755.26, a PE ratio of 20.80, a price-to-earnings-growth ratio of 2.33 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same period last year, the firm earned $0.77 earnings per share. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. sell-side analysts anticipate that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.61%. Bristol-Myers Squibb’s payout ratio is 61.42%.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II purchased 4,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were acquired at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the transaction, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.

Several equities research analysts recently commented on BMY shares. Jefferies Group reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price objective on the stock in a research report on Wednesday, September 27th. Goldman Sachs Group reaffirmed a “buy” rating and issued a $65.00 price objective (up from $62.00) on shares of Bristol-Myers Squibb in a research report on Thursday, September 7th. UBS reaffirmed a “buy” rating and issued a $72.00 price objective (up from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Finally, Citigroup boosted their price objective on shares of Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $64.93.

TRADEMARK VIOLATION WARNING: “APG Asset Management N.V. Has $102.91 Million Holdings in Bristol-Myers Squibb Co (BMY)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/21/apg-asset-management-n-v-has-102-91-million-holdings-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.